October 21, 2005 |
Faced with the possibility of a worldwide epidemic of bird flu, the maker of the antiviral medication Tamiflu has agreed to discuss deals with generic pharmaceutical manufacturers that would increase production of the drug, which is in short supply, lawmakers said Thursday. Tamiflu is not a vaccine, but some doctors believe that if administered early it can reduce the severity of the illness and help prevent its spread. Sens. Charles E. Schumer (D-N.Y.) and Lindsey Graham (R-S.C.
January 21, 1997 |
Swiss drug maker Roche Holding said it signed an agreement with Agouron Pharmaceuticals Inc. that will give it exclusive rights to sell the U.S. drug maker's Viracept HIV treatment in Europe. Roche said it will pay $9 million each to La Jolla-based Agouron and to Japan Tobacco Inc., with which Agouron developed Viracept, and will pay an additional $11 million to each upon European clearance of the drug. Agouron filed for U.S.
June 9, 1990 |
Shareholders of biotechnology pioneer Genentech voted overwhelmingly Friday to approve the company's $2.1-billion merger with Roche Holding, a Swiss pharmaceutical giant, despite last-ditch efforts by disgruntled longtime investors to derail the plan. At the end of a rancorous annual meeting in Millbrae, south of San Francisco, the company said 97% of those voting favored the deal.
December 15, 1994 |
Consolidation in the $30-billion medical-testing business accelerated Wednesday as La Jolla-based National Health Laboratories and Swiss-owned Roche Biomedical Laboratories said they would merge into the nation's largest diagnostic laboratory chain. Company officials and analysts said the merger idea was a response to intense price pressure coming from cost-conscious managed-care firms and the federal government. The combination of the third-largest and fourth-largest U.S.
November 17, 2003 |
What is now a contest between Amgen Inc. and Johnson & Johnson over the lucrative anemia drug business could soon become a three-way race. At a medical meeting here this weekend, Swiss drug maker Roche said it was ready to begin the final round of human tests needed for government approval of Cera, its investigational anemia drug.
July 20, 1999 |
Roche Holding's sale Monday of 20 million shares in Genentech raised $1.94 billion, a record for the biotechnology industry and the third-largest U.S. initial public offering of the year. Switzerland-based Roche sold the 16% stake in Genentech at $97 a share, near the top of an $88-$98 range set by J.P. Morgan Securities, which managed the sale. The deal produced a quick profit for the Swiss drug maker, which in June exercised an option to buy, for $82.
June 4, 1999 |
Apparently, Web-site glitches aren't enough to keep a good online broker down. On Thursday, the electronic-commerce research firm Gomez Advisors updated its "Internet Broker Scorecard" and named E-Trade the best online broker overall. Charles Schwab finished third. Yet, relative to some peers, both are considered expensive. E-Trade charges $19.95 for a basic Nasdaq trade, Schwab $29.95. By comparison, SureTrade charges $7.95.
May 27, 1997 |
Swiss pharmaceutical giant Roche Holding will buy holding company Corange for $11 billion in a deal that will make it a world leader in the medical diagnostics business. Roche announced Monday it will take over Corange's holdings in Germany's Boehringer Mannheim, a market leader in cardiovascular and cancer treatments. It will also gain an 84.2% stake in DePuy, a Warsaw, Ind.-based producer of orthopedic products that had an initial public offering in October.
March 5, 2008 |
Roche Holding and GlaxoSmithKline said Tuesday that they had added new labels to their prescription flu medicines that contain reports of abnormal psychiatric behavior in some patients. A warning about cases of delirium and unusual behavior had been listed previously on Roche's drug, Tamiflu. That language was strengthened to say some cases were fatal.
May 26, 1999 |
Roche Holding and BASF, which last week agreed to pay record U.S. fines totaling $725 million for conspiring to fix global vitamin prices, may also face stiff European Union fines, EU Competition Commissioner Karel Van Miert suggested. A resolution to the EU's own investigation is still months away, however, and Van Miert would not say which companies the EU may fine. Roche, Europe's fourth-biggest drug maker, agreed last week to pay $500 million--the largest U.S.